Serum level of interleukin-13 receptor alpha 2 in infants with biliary atresia – is it of value?

Nermin Adawy; Hanaa El-Araby; Alif Allam; Soha Elshenawy; Mohammed Khedr; Yasmine Ibrahim; Haidy M. Zakaria

doi:10.5114/ceh.2018.75958

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2018
vol. 4

Send email

Copy url:

abstract:

Original paper

Serum level of interleukin-13 receptor alpha 2 in infants with biliary atresia – is it of value?

Nermin Adawy

,

Hanaa El-Araby

,

Alif Allam

,

Soha Elshenawy

,

Mohammed Khedr

,

Yasmine Ibrahim

,

Haidy M. Zakaria

Clin Exp HEPATOL 2018; 4, 2: 91-96

DOI: https://doi.org/10.5114/ceh.2018.75958

Online publish date: 2018/05/25

View full text Get citation

PlumX metrics:

Aim of the study
We aimed to assess the utility of serum level IL-13Rα2 receptors as a non-invasive marker for early diagnosis of biliary atresia (BA) and selection of BA patients indicated for Kasai portoenterostomy.

Material and methods
The study included 60 infants with neonatal cholestasis in three groups; early BA group (n = 20), delayed BA group (n = 20) and non-BA cholestasis group (n = 20). A fourth group of 20 healthy neonates (n = 20) served as controls. IL-13Rα2 was measured by enzyme-linked immunosorbent assay in all patients and controls.

Results
The mean value of IL-13Rα2 was significantly higher in delayed BA group (11.05 ± 10.9 ng/ml) compared to early BA (0.34 ± 0.37 ng/ml), non-BA (0.54 ± 0.85 ng/ml) and control (0.24-0.2 ng/ml) groups. The levels of serum IL-13Rα2 increase with the severity of the degree of fibrosis. IL-13Rα2 at a cutoff level > 0.782 ng/mlcould predict late fibrosis with accuracy of 77.55% (p < 0.0001). IL-13Rα2 could differentiate between preserved and disturbed liver architecture at a cut off value of more than 0.42 ng/ml with an accuracy of 81.6%.

Conclusions
Serum IL-13Rα2 not a diagnostic marker for BA however it could be used as a noninvasive marker for detection of advanced liver fibrosis and presence of disturbed liver architecture that helps in patient selection for undergoing Kasai operation. Serum IL-13Rα2 could be a future therapeutic target for management of BA patients and any fibrotic liver disease.

keywords:

Serum level of interleukin-13 receptor alpha 2 in infants with biliary atresia – is it of value?

Nermin Adawy , Hanaa El-Araby , Alif Allam , Soha Elshenawy , Mohammed Khedr , Yasmine Ibrahim , Haidy M. Zakaria

cholestasis, liver fibrosis, biliary atresia, interleukin-13Rα2, Kasai portoenterostomy

Nermin Adawy

,

Hanaa El-Araby

,

Alif Allam

,

Soha Elshenawy

,

Mohammed Khedr

,

Yasmine Ibrahim

,

Haidy M. Zakaria